Davis Polk advised the dealer managers in connection with Biogen’s offer to exchange its outstanding 5.200% senior notes due 2045 for a new series of senior notes due 2051.
Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Biogen is focused on discovering, developing and delivering worldwide innovative therapies in emerging growth areas of immunology; neurocognitive disorders; acute neurology and pain.
The Davis Polk capital markets team included partner Michael Kaplan, counsel Radoslaw Michalak and associate Johnathan M. Nixon. The tax team included partner Mario J. Verdolini and associate Erin van Wesenbeeck. Partner David R. Bauer, counsel Bonnie Chen and associate Chelsea Renter provided intellectual property advice. All members of the Davis Polk team are based in the New York office.